Percorrer por autor "Hasani, Motahareh"
A mostrar 1 - 4 de 4
Resultados por página
Opções de ordenação
- Does vitamin D supplementation impact serotonin levels? A systematic review and meta-analysis.Publication . Alimohammadi-Kamalabadi, Malek; Ziaei, Somayeh; Hasani, Motahareh; Mohammadi, Shooka; Mehrbod, Milad; Morvaridi, Mehrnaz; Persad, Emma; Belančić, Andrej; Malekahmadi, Mahsa; Estêvão, Maria Dulce da Mota Antunes de Oliveira ; Daneshzad, Elnaz; Heshmati, JavadVitamin D deficiency impacts a significant proportion of the world's population, and this deficiency has been linked to various conditions characterized by imbalanced serotonin regulation. The objective of this systematic review and meta-analysis was to evaluate the effect of vitamin D supplementation on serum serotonin levels. We conducted a comprehensive search of PubMed, Scopus, Cochrane Central for Randomized Clinical Trials, and Web of Science up to September 2022, without any language restrictions. The effect sizes were calculated using the standard mean difference (SMD) and 95% confidence interval (CI). Six randomized clinical trials involving 356 participants were included in the analysis. Our findings indicated no significant changes in serotonin levels between the intervention and control groups (SMD: 0.24 ng/mL, 95% CI: -0.28, 0.75, > 0.10). Subgroup analysis also did not reveal any significant changes in serotonin levels among children, participants with autism spectrum disorders, interventions lasting 10 weeks or longer, or those receiving vitamin D doses below 4000 IU/day. Although the results obtained in this systematic review are inconclusive, they support the need for further well-designed randomized trials to assess the potential role of vitamin D supplementation in regulating serotonin levels and potentially ameliorating depression and related disorders.
- Effect of saffron supplementation on liver enzymes: a systematic review and meta-analysis of randomized controlled trialsPublication . Hasani, Motahareh; Malekahmadi, Mahsa; Rezamand, Gholamreza; Estêvão, M. Dulce; Pizarro, Ana Beatriz; Heydari, Hafez; Hoong, Wong Chun; Arafah, Omar Ahnaf; Barakeh, Abdul Rahman Riad; Rahman, Areej; Alrashidi, Mona Saud K.; Abu-Zaid, AhmedBackground and aims: Possible protective effects of saffron (Crocus sativus L) have been reported in several randomized clinical trials (RCTs). Current systematic review was performed to summarize the efficacy of saffron intake on liver enzymes. Methods: An electronic database search was conducted on PubMed/Medline, Scopus, Web of Science, and Cochrane for RCTs comparing effect of saffron and placebo on liver enzymes from inception to July 2021. There was no restriction in language of included studies and we calculated the standardized mean difference (SMD) and 95% Confidence Intervals (CI) for each variable. Random-effect model was used to calculate effect size. Results: Eight studies (n = 463 participants) were included in the systematic review. The saffron intake was associated with a statistically significant decrease in aspartate aminotransferase (AST) (SMD: -0.18; 95% CI: -0.34, -0.02; I-2 = 0%) in comparison to placebo intake. Our results also indicated that saffron consumption did not have a significant effect on alanine aminotransferase (ALT) (SMD: -0.14; 95% CI: -0.36, 0.09; I-2 = 47.0%) and alkaline phosphatase (ALP) levels (SMD: 0.14; 95% CI: -0.18, 0.46; I-2 = 42.9%) compared to placebo. Conclusions: Saffron intake showed beneficial impacts on circulating AST levels. However, larger well-designed RCTs are still needed to clarify the effect of saffron intake on these and other liver enzymes.
- Effects of vitamin D supplementation on bone health and bone-related parameters in HIV-infected patients: A systematic review and meta-analysisPublication . Rezamand, Gholamreza; Estêvão, M. Dulce; Morvaridzadeh, Mojgan; Akbari, Abolfazl; Tabaeian, Seidamir Pasha; Pizarro, Ana Beatriz; Malekahmadi, Mahsa; Hasani, Motahareh; Roffey, Darren M.; Mirzaei, Alireza; Heshmati, JavadPurpose: There is growing evidence that bone health is decreased in individuals with HIV infection. Vitamin D deficiency is also highly prevalent among HIV-infected patients. The literature was systematically reviewed to determine whether bone health and bone-related parameters may improve with vitamin D supplementation in HIV-infected individuals. Methods: Four databases were systematically searched for randomized clinical trials of vitamin D supplementation in HIV infection, published from January 1990 to September 2021. No language or publication restrictions were applied. Standardized mean differences (SMD) with 95% CIs are reported. A random-effects model was used to perform meta-analysis. Findings: Ten studies met the inclusion criteria (N = 733 participants at study completion). The mean ages of the patients in the included trials ranged from 10 to 49 years. The meta-analysis indicated that with vitamin D supplementation, serum 25-hydroxy vitamin D (25[OH]D) level was significantly increased (SMD, 1.86; 95% CI, 1.02 to 2.70; I-2 = 94.4%), but there were no significant effects on levels of serum 1,25-dihydroxy vitamin D (1,25-[OH](2)D) (SMD, 0.29; 95% CI, -0.07 to 0.64; I-2 = 67.4%), total bone mineral density (SMD, 0.07; 95% CI, -0.23 to 0.37; I-2 = 00.0%), spine bone mineral density (SMD, 0.15; 95% CI, -0.19 to 0.49; I-2 = 17.3%), and parathyroid hormone level (SMD, -0.18; 95% CI, -0.37 to 0.02; I-2 = 1.2%) in HIV-infected patients. (C) 2022 Elsevier Inc.
- Sumac fruit supplementation improve glycemic parameters in patients with metabolic syndrome and related disorders: a systematic review and meta-analysisPublication . Ghafouri, Atie; Estêvão, M. Dulce; Alibakhshi, Pooya; Pizarro, Ana Beatriz; Kashani, Amirhossein Faghihi; Persad, Emma; Heydari, Hafez; Hasani, Motahareh; Heshmati, Javad; Morvaridzadeh, MojganBackground: Metabolic syndrome (MetS) is the one of the main causes of mortality worldwide. Several randomized controlled trials (RCTs) have revealed the beneficial effects of sumac (Rhus coriaria) on cardiometabolic risk factors. However, the entirety of the evidence has yet to be summarized in a systematic review. Objective: The aim of this systematic review and meta-analysis was to evaluate the effects of sumac on several cardiometabolic risk factors in patients with MetS and related disorders. Methods: We reviewed Medline, Scopus, Web of Science and Cochrane CENTRAL for RCTs published from inception to December 2020 evaluating the impact of sumac in adults with MetS or related disorders. Outcome measures included anthropometric measures, glycemic indices, blood lipids, blood pressure and liver enzymes. Pooled effect sizes were reported as standard mean differences (SMDs) and 95% confidence intervals (CIs). Trials were pooled using a random effects model. Results: Nine studies enrolling 526 participants met the inclusion criteria for this meta-analysis. Our results indicate that sumac intake significantly decrease fasting blood sugar (FBS) (SMD: 0.28; 95% CI: 0.54, -0.02; I-2 = 00.0%), insulin (SMD: 0.67; 95% CI: 0.99, -0.36; I-2 = 03.7%), and insulin resistance (measured through the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)) (SMD: 0.79; 95% CI: 1.24, -0.34; I-2 = 50.1%). Sumac intake did not have a significant impact on weight, body mass index (BMI), waist circumference (WC), hip circumference (HC), waist to hip ratio (WHR), HbA1c, total cholesterol (TC), triglycerides (TG), high density lipoproteins (HDL), low density lipoprotein (LDL), systolic blood pressure (SBP), diastolic blood pressure (DBP), aspartate transaminase (AST) and alanine transaminase (ALT). Conclusion: Sumac, as an adjuvant therapy, may decrease serum levels of FBS, insulin and HOMA-IR. However, due to high heterogeneity in the included studies, these findings must be interpreted with great caution. Larger, well-designed placebo-controlled clinical trials are still needed to further evaluate the capacity of sumac as a complementary treatment to control MetS risk factors.